Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone

Antiviral Therapy

Volumn 14, Issue 1, 2009, Pages 55-61

  Morfin, Florence ^a,b   Dupuis Girod, Sophie ^c,d   Frobert, Emilie ^a   Mundweiler, Stéphanie ^a,b   Carrington, David ^e   Sedlacek, Petr ^f   Bierings, Marc ^g   Cetkovsky, Petr ^h   Kroes, Aloys C M ⁱ   van Tol, Maarten J D ⁱ   Thouvenot, Danielle ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c HÔPITAL DEBROUSSE   (France)

^d HÔTEL DIEU   (France)

^e Regional Virus Laboratory   (United Kingdom)

^f UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; RIBAVIRIN;

ADENOVIRUS; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; GENOTYPE; HUMAN; HUMAN CELL; IC 50; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SPECIES DIFFERENCE; VIRUS INFECTION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION;

ADENOVIRIDAE; ADENOVIRUS INFECTIONS, HUMAN; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CYTOSINE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HUMANS; PHOSPHONIC ACIDS; RIBAVIRIN; SEROTYPING; SPECIES SPECIFICITY;

EID: 61849139529     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Morfin F. Boucher A, Najioullah F, et al. Cytomegalovirus and adenovirus infections and diseases among 75 paediatric unrelated allogeneic bone marrow transplant recipients. J Med Virol 2004; 72:257-262.
2. Walls T, Shankar AG, Shingadia D. Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. Lancet Infect Dis 2003; 3:79-86.
3. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43:331-339.
4. Lenaerts L, Naesens L. Antiviral therapy for adenovirus infections. Antiviral Res 2006; 71:172-180.
5. Leruez-Ville M, Chardin-Ouachee M, Neven B, et al. Description of an adenovirus A31 outbreak in a paediatric haematology unit. Bone Marrow Transplant 2006; 38:23-28.
6. Ribaud P, Scieux C, Freymuth F, Morinet F, Gluckman E. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis 1999; 28:690-691.
7. Cassano WF, Intravenous ribavirin therapy for adenovirus cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1991; 7:247-248.
8. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:388-394.
9. Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31:481-486.
10. Nagafuji K, Aoki K, Henzan H, et al. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2004; 34:909-914.
11. Muller WJ, Levin MJ, Shin YK, et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis 2005; 41:1812-1816.
12. Yusuf U, Hale GA, Carr J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006; 81:1398-1404.
13. Neofytos D, Ojha A, Mookerjee B, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007; 13:74-81.
14. Walls T, Hawrami K, Ushiro-Lumb I, Shingadia D, Saha V, Shankar AG. Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary? Clin Infect Dis 2005; 40:1244-1249.
15. Hromas R, Clark C, Blanke C, et al. Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14:663-664.
16. Crooks BN, Taylor CE, Turner AJ, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant 2000; 26:1097-1102.
17. Lankester AC, Heemskerk B, Claas EC, et al. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin Infect Dis 2004; 38:1521-1525.
18. Arav-Boger R, Echavarria M, Forman M, Charache P, Persaud D. Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient. Pediatr Infect Dis J 2000; 19:1097-1100.
19. Miyamura K, Hamaguchi M, Taji H, et al. Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors. Bone Marrow Transplant 2000; 25:545-548.
20. Morfin F, Dupuis-Girod S, Mundweiler S, et al. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther 2005; 10:225-229.
21. Langlois M, Allard JP, Nugier F, Aymard M. A rapid and automated colorimetric assay for evaluating the sensitivity of herpes simplex strains to antiviral drugs. J Biol Stand 1986; 14:201-211.
22. Swenson P. Adenoviruses. In Lennette EH, Smith TF, editors. Laboratory diagnosis of viral infections. New York: Marcel Dekker 1999; pp. 287-303.
23. Romanowski EG, Gordon YJ, Araullo-Cruz T, Yates KA, Kinchington PR. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model. Invest Ophthalmol Vis Sci 2001; 42:1812-1815.
24. Field HJ. A perspective on resistance to acyclovir in herpes simplex virus. J Antimicrob Chemother 1983; 12 Suppl B:129-135.
25. Stock R, Harste G, Madisch I, Heim A. A rapid quantitative PCR-based assay for testing antiviral agents against human adenoviruses demonstrates type specific differences in ribavirin activity. Antiviral Res 2006; 72:34-41.
26. Snell NJC. Ribavirin - current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2001; 2:1317-1324.
27. Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 2006; 16:37-48.
28. Allen LB, Boswell KH, Khwaja TA, et al. Synthesis and antiviral activity of some phosphates of the broad-spectrum antiviral nucleoside, 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin). J Med Chem 1978; 21:742-746.
29. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 177:705-706.
30. Wildner O, Hoffmann D, Jogler C, Uberla K. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Ther 2003; 10:791-802.
31. Kirsi JJ, North JA, McKernan PA, et al. Broad-spectrum antiviral activity of 2-β-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob Agents Chemother 1983; 24:353-361.
32. Baba M, Mori S, Shigeta S, De Clercq E. Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine and 2′-nor-cyclic GMP on adenovirus replication in vitro. Antimicrob Agents Chemother 1987; 31:337-339.
33. Naesens L, Lenaerts L, Andrei G, et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 20O5; 49:1010-1016.